|
Mar 6
|
Q4 2023 Seres Therapeutics Inc Earnings Call
|
|
Mar 5
|
Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023
|
|
Mar 5
|
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
|
|
Jan 9
|
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
|
|
Jan 4
|
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 8
|
Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023
|
|
Dec 2
|
Seres Therapeutics, Inc. (NASDAQ:MCRB) is a favorite amongst institutional investors who own 62%
|
|
Nov 28
|
Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET
|
|
Nov 5
|
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million
|
|
Aug 9
|
Investors Don't See Light At End Of Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Tunnel
|
|
Aug 8
|
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
|
|
Aug 8
|
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
|